Ceterix Orthopaedics raises $19.5M for safe suture device
January 14, 2013 by MassDevice staff
Surgical tools maker Ceterix Orthopaedics raises a $19.5 million funding round.
Ceterix Orthopaedics landed $19.5 million from 5 investers, according to a regulatory filing.
The Menlo Park, Calif-based surgical tools maker said it plans to raise an additional $1.10 million, Medcity News reported.
Sign up to get our free newsletters delivered right to your inbox.
Similar entries
Ceterix is developing a suturing device designed to help surgeons stitch difficult anatomies while avoiding surrounding tissue, cartilage or adjacent nerves, according to its website.
Ceterix in 2010 raised an $8.1 million Series A round from Versant Ventures and 5AM Ventures, according to Medcity News.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Medical device tax: Consultant calls offshoring concerns 'horse hockey'
Concerns that the medical device tax will push companies to lay off workers and move operations...
FDA clears OrthoSensor's Verasense knee replacement device
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical wins CE Mark for peripheral catheter
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
Recalls: FDA makes Endologix catheter introducer recall Class I
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
pSivida gains big on buyout rumor
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...
